AI Article Synopsis
- Some patients experience side effects, including cytopenias, especially when taking interferon-α-2a with ribavirin for hepatitis C.
- This text highlights a case where a patient with primary myelofibrosis developed reversible bone marrow aplasia due to pegylated interferon, underscoring the importance of monitoring for such serious side effects.
Article Abstract
Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1078155213504444 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!